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Abstract
Background: Epidemiological studies and anecdotal reports suggest a possible link between household use of hard water
and atopic eczema. We sought to test whether installation of an ion-exchange water softener in the home can improve
eczema in children.
Methods and Findings: This was an observer-blind randomised trial involving 336 children (aged 6 months to 16 years) with
moderate/severe atopic eczema. All lived in hard water areas ($200 mg/l calcium carbonate). Participants were randomised
to either installation of an ion-exchange water softener plus usual eczema care, or usual eczema care alone. The primary
outcome was change in eczema severity (Six Area Six Sign Atopic Dermatitis Score, SASSAD) at 12 weeks, measured by
research nurses who were blinded to treatment allocation. Analysis was based on the intent-to-treat population. Eczema
severity improved for both groups during the trial. The mean change in SASSAD at 12 weeks was 25.0 (20% improvement)
for the water softener group and 25.7 (22% improvement) for the usual care group (mean difference 0.66, 95% confidence
interval 21.37 to 2.69, p=0.53). No between-group differences were noted in the use of topical corticosteroids or
calcineurin inhibitors.
Conclusions: Water softeners provided no additional benefit to usual care in this study population. Small but statistically
significant differences were found in some secondary outcomes as reported by parents, but it is likely that such
improvements were the result of response bias, since participants were aware of their treatment allocation. A detailed
report for this trial is also available at http://www.hta.ac.uk.
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Atopic eczema is a chronic, itchy, inflammatory skin condition
that commonly involves the skin creases. It is associated with
asthma, hay fever, food allergy, and atopy. The term atopic
eczema is synonymous with atopic dermatitis. The World Allergy
Organisation now suggests that the phenotype of atopic eczema
should be called just eczema unless specific IgE antibodies are
demonstrated [1], and we will use the term eczema throughout
this report. Eczema is very common, affecting around 20% of
school children in developed countries [2]. Eczema can cause
intractable itching leading to thickened skin, bleeding, secondary
infection, sleep loss, poor concentration, and psychological distress
to the child and the entire family [3]. The cost of treating eczema
is substantial, both for the health provider and for families [4,5].
Epidemiological evidence linking increased water hardness with
increased eczema prevalence was first demonstrated in an
ecological study of 4,141 randomly selected primary school
children living around Nottingham, UK [6]. The 1-year period
prevalence of eczema was 17.3% in the hardest water category
and 12.0% in the lowest (odds ratio 1.54, 95% confidence interval
[CI] 1.19–1.99 after adjustment for confounders). Similar but
smaller gradients have since been reported in Japan [7] and Spain
[8]. It is possible that hard water could exacerbate eczema,
because hard water results in more soap and detergent use, which
can directly irritate the dry skin found in people with eczema.
Soap also reacts with calcium in hard water to form small chalk
particles which can irritate eczematous skin. Indirect effects such
as enhanced allergen penetration due to a disruption in the skin
barrier [9], and increased bacterial colonisation of the skin, are
also plausible mechanisms of how hard water could worsen
eczema symptoms [10].
Current pharmacological treatments for eczema have their
limitations; topical corticosteroids may cause skin thinning [11],
and the long-term safety of topical tacrolimus and pimecrolimus is
still uncertain [11]. Given such concerns about pharmacological
treatments, it is not surprising that interest in a nonpharmacolog-
ical treatment that has no apparent side effects is high. There have
been widespread anecdotal reports of improvement in the skin of
people with eczema when moving from a hard- to a soft-water
area. Anecdotal reports from patients also report rapid improve-
ment in the symptoms of eczema following installation of a water
softener. A previous systematic review of eczema treatments failed
to identify any relevant trials evaluating the potential benefit of
water softeners for eczema [12]. In view of the limited evidence for
water softeners in eczema, the high public interest in their
potential benefit, and low risk of adverse effects, the UK National
Institute for Health Research Health Technology Assessment
programme prioritised and commissioned the Softened Water
Eczema Trial (SWET).
The SWET had two main objectives: (1) to assess whether the
installation of an ion-exchange water softener reduces the severity
of eczema in children with moderate to severe eczema, and if so,
(2) to establish the likely cost and cost-effectiveness of the
intervention.
Methods
Details of the study protocol have been reported previously [13].
The study was approved by North West Research Ethics
Committee (Ref 06/MRE08/77) and written informed consent
was provided by the parent/caregiver of participating children
(with signed assent from older children as appropriate). Copies of
the trial protocol and CONSORT statement are available as
supporting information (Text S1 and Text S2, respectively).
Study Design
The SWET trial was an observer-blind, parallel-group rando-
mised trial of 12 weeks duration, followed by a 4-week
observational period. Participants were randomised to receive
either immediate installation of an ion-exchange water softener
plus their normal eczema care (Group A) or normal eczema care
alone (Group B). Only one child per household was randomised
into the study. The primary outcome was assessed at 12 weeks,
after which time the water softeners were removed for participants
in Group A, or installed for a period of 4 weeks for those in Group
B. The observational period between weeks 12 and 16 was
included as initial pilot work suggested that participants valued the
opportunity to try a ‘‘real’’ softener for themselves, and because it
provided an opportunity to look at speed of onset of benefit and
duration of treatment effects.
The trial used an observer-blind design, as a previous pilot trial
involving real and ‘‘dummy’’ units [14] suggested that it was not
possible to blind participants to their treatment allocation because
the softened water produced more suds. When a double-blind
design is not possible, it is essential to ensure that the outcome
assessment is free of observer bias [15]. We achieved this by using
trained research nurses to conduct an objective assessment of the
child’s skin at baseline, 4, 12, and 16 weeks.
Protocol
A full copy of the final trial protocol and the analysis plan are
available at http://www.swet-trial.co.uk. Changes to the protocol
following ethics committee approval in January 2007 included
minor amendments to trial documents, the inclusion of amounts of
topical medications as an additional secondary outcome measure,
and an end of trial follow-up questionnaire. One of the secondary
outcomes (patient-assessed global improvement in eczema) was
replaced with broad categories as defined by the SASSAD score
(the proportion of children who had a reasonable (#20%), good
(.20% and #50%) or excellent (.50%) improvement in
SASSAD score), as this was felt to be more appropriate in a
single-blind study. All amendments were implemented before
breaking of the treatment allocation code and before finalising the
analysis plan.
Recruitment
Recruitment took place between May 2007 and June 2009, in
eight UK centres (Nottingham, Cambridge, London [2 centres],
Isle of Wight, Portsmouth, Lincoln, and Leicester). Participants
were identified through secondary care referral centres, primary
care, or in response to publicity. For those living in rented
accommodation, approval to install the unit was obtained from the
landlord of the property (including both private and Council
tenants). All lived in hard-water areas ($200 mg/l calcium
carbonate) and had a home suitable for straightforward installation
of a water softener.
Three hundred thirty-six children aged 6 months to 16 years
were enrolled in the trial. All had a diagnosis of eczema according
to the UK working party’s diagnostic criteria [16] and a minimum
eczema severity score of ten points using the Six Area Six Sign
Atopic Dermatitis severity score (SASSAD) [17]. Children with a
SASSAD score of less than ten points were excluded to avoid
possible floor effects in measuring treatment response. Children
were also excluded if they planned to be away from the home for
.21 days during the 12-week study period (to ensure adequate
exposure to the intervention), if they had taken systemic
medication (e.g., cyclosporin or UV light therapy) in the last 3
months or oral steroids in the last 4 weeks, if they had started a
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water treatment device installed in the home.
Interventions
Ion-exchange water softeners plus usual eczema care were
compared with usual eczema care alone. Ion-exchange water
softeners use a synthetic polystyrene resin to remove calcium and
magnesium ions from household water, replacing them with
sodium ions, thus eliminating the hardness. The resin becomes
depleted of sodium and is recharged using sodium chloride
(common salt). To avoid favouring any one company, a generic
unit was produced for the trial. The units met all necessary
regulatory standards and were installed by trained water engineers
according to British Water’s code of practice [18]. Water samples
were tested once a week to check that the units were working
correctly. Any samples with a reading of .20 mg/l calcium
carbonate were referred to the engineer for investigation.
For those allocated to Group A, a water softener unit was
installed in the child’s main residence as soon as possible after the
baseline visit. All water entering the home was softened, with the
exception of a drinking water tap at the side of the kitchen sink
(unless this was refused by the participant or was technically too
difficult to install). Participants were asked to bathe and wash their
clothes in the usual way. A written booklet provided at the time of
installation of the softeners gave general advice about use of the
water softener. This included instructions to (1) check the salt
regularly, (2) send water samples for analysis on a weekly basis, and
(3) to reduce soap usage by at least half, in line with general advice
on the use of water softeners in the home [19].
Participants allocated to delayed installation (Group B), received
an active unit after the primary outcome had been collected at 12
weeks.
Both groups received a support telephone call from the
coordinating centre at 8 weeks, and all participants continued
with their usual eczema care for the duration of the trial. Usual
care was defined as any treatment that the child was currently
using to control their eczema (e.g., topical corticosteroids,
emollients). Participants were discouraged from starting new
treatments during the period of the trial. Any patients who started
new treatments were defined as protocol violators and excluded
from the per-protocol analysis.
Outcomes
Primary outcome was the difference between Groups A and B
in mean change in disease severity at 12 weeks compared with
baseline, as measured using SASSAD [17]. This was chosen as the
primary outcome because SASSAD has been used extensively in
other clinical trials of eczema [20,21] and because we had personal
experience of using the scale in a clinical trial setting. It is easy and
quick to complete, does not require an assessment of surface area
involvement (which is extremely difficult to do reliably in patients
with eczema) [22], and most importantly it is entirely performed
by the observer, making it a good objective outcome measure for
this observer-blind trial. Research nurses were trained in the use of
the scale by either a dermatologist or a dermatology nurse
consultant. Training was deemed complete when scores were
,10% of each other. As far as possible the same nurse conducted
baseline and follow-up assessments for individual participants. A
reduction in the SASSAD score represents an improvement in
eczema severity.
Secondary outcomes were differences in the following measures.
(1) Proportion of time spent moving during the night. This is an
objective surrogate for sleep loss and itchiness, which are two
of the defining features of eczema [23,24]. Nighttime
movement was captured using wrist accelerometers (Acti-
watch Mini, supplied by CamNtech Ltd, Cambridge, UK),
and measured at baseline and at 12 weeks.
(2) Proportion of children who had the same or a worse outcome
(#0%) or had a small (.0% and #20%), good (.20% and
#50%), or excellent (.50%) improvement in SASSAD score.
(3) Amount of topical corticosteroid or calcineurin inhibitors
used.
(4) Patient Oriented Eczema Measure [25].
(5) Number of totally controlled week(s) (TCW) and well-
controlled week(s) (WCW) [26].
(6) Mean change in the Dermatitis Family Impact (DFI)
questionnaire [27].
(7) Mean change in health related quality of life (children’s
version of the EQ-5D for children aged 7 years and over, or
the proxy version of the EQ-5D for children aged 3 to 6 years)
[28].
In addition, a subgroup analysis was planned for participants
with at least one of the two most common mutations of the gene
encoding filaggrin (loss-of-function mutations R501X and
2282del4). Filaggrin is a protein whose deficiency might predispose
to impaired skin barrier function and enhanced benefit from water
softening [9].
All outcomes were collected during clinic assessments with the
research nurse at baseline, 4, 12 and 16 weeks, or through daily
diaries.
As the intervention involved the use of a commonly available
household technology with no known side-effect, adverse events
were not anticipated nor collected during the trial.
Sample Size
Sample size estimates were based on published data relating to
the use of SASSAD in patients recruited in secondary care
[17,21,29]. Using an unpaired t-test with equal variance, a sample
size of 310 children provided 90% power, with a significance level
of 5% (assuming an attrition rate of 15%). This was based on a
minimum clinically relevant difference between the groups of 20%
in the change in SASSAD score, assuming a mean baseline score
of 20 and no improvement in the usual-care arm. The standard
deviation for the change in SASSAD score was assumed to be 10
[29].
For the planned subgroup analysis of children with at least one
mutation in the filaggrin gene, a total of 90 children with the
mutation was sufficient to detect a 30% difference between the
treatment groups in the primary outcome, with 80% power, 5%
significance, and a standard deviation of 10.
Randomisation and Blinding
Participants were randomised using a web-based randomisation
tool and were allocated on a 1:1 basis according to a computer-
generated code, using random permuted blocks of randomly
varying size. The programme was created by the Nottingham
Clinical Trials Unit (CTU), and held on a secure server.
Randomisation was stratified by disease severity (baseline
SASSAD #20, or SASSAD score .20) and recruiting centre.
Access to the sequence was confined to the CTU Data Manager.
The allocation group was indicated to the trial manager only after
baseline data had been irrevocably entered into the randomisation
programme. The sequence of treatment allocations was concealed
until all interventions had been assigned and recruitment, data
collection, and analysis were complete.
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throughout the trial and the statistician analysed the results based
on treatment code, using an analysis plan that was finalised before
the coded allocation sequence was revealed. The only trial
personnel in direct contact with participants were the research
nurses and water engineers. The trial manager and study support
staff at the coordinating centre in Nottingham had telephone
contact with parents of participants. Trial participants continued
to see their normal health care professionals for their ongoing
eczema care.
Participants were discouraged from discussing their treatment
allocation with the research nurse, and the importance of
maintaining ‘‘blinding’’ was highlighted in the participant
information sheets.
Statistical Methods
Analyses were performed by CO (author) in Stata 10.1 [30].
Results were analysed based on treatment code, using an analysis
plan that had been finalised prior to locking the database.
Reported p-values are two-sided, with a significance level of 5%.
The primary outcome was analysed as intent-to-treat (ITT) using
the randomised treatment allocation rather than actual treatment
received. Only participants with complete data were included in
the ITT analysis, as the analysis plan specified that imputation of
missing values was not required if less than 5% of data were
missing. Baseline characteristics were summarised and an adjusted
analysis was conducted where major imbalances existed. An
additional per-protocol analysis was performed excluding protocol
violators; these were determined before treatment allocation was
decoded (for further details of protocol violators please see full trial
report) [14].
The average percentage of the night spent moving was
calculated by taking the average of the first 3 nights of usable
data at baseline and the last 3 nights of usable data at week 12, as
these days were closest to the nurses’ assessments of eczema
severity. Data were collected on the proportion of the night spent
moving, regardless of sleep status (awake/asleep). Usable data
were defined as values between 5% and 95% of the night spent
moving to exclude outliers.
The total amount of medication used during the 12-week study
period was measured by weighing the medication at each visit.
The number of TCW and WCW were compared. A TCW was
defined as a week with 0 days with an eczema bother score .4 and
0 days in which ‘‘stepping up’’ of treatment was required. Stepping
up of treatment was treatment over and above that defined as
‘‘normal’’ for an individual participant in the daily symptom
diaries. Bother scores were assessed on a scale of 0 to 10 in answer
to the following question: How much bother has your child’s eczema been
today? A WCW was defined as a week with #2 days with an
eczema bother score .4 and #2 days where ‘‘stepping up’’ was
required.
All other outcomes were scored according to the guidelines for
the scale and compared the mean change from baseline to week
12. Continuous data were analysed using a t-test and categorical
data were analysed using a Chi-squared test for trend.
Results
A total of 336 participants were enrolled in the trial. Of those
allocated to Group A, the water softeners were installed an average
of 12 days after randomisation into the trial (SD 5.5). The average
duration of installation was 74 days (SD 7.6). Twenty-one hardness
alerts (sample readings of .20 mg/l calcium carbonate) were
received during the 12-week trial period. These were resolved
within 8 days on average (SD 4.5).
The ITT population included 159 participants in Group A
(water softener+usual care) and 164 in Group B (usual care). One
participant was excluded because of incomplete data at baseline,
and 12 participants withdrew from the trial before the primary
endpoint at week 12 (Figure 1).
We found no difference between the groups in the primary
outcome of disease severity. The mean change in the SASSAD
score at 12 weeks compared to baseline was 25.0 (a 20%
improvement) in Group A and 25.7 (a 22% improvement) in
Group B. The mean change in disease severity between the two
groups at 12 weeks was 0.66 (95% CI 21.37 to 2.69; p=0.53) in
favour of Group B. An additional analysis adjusting for
stratification variables (baseline SASSAD and centre) was
performed, but this did not alter the conclusion. The difference
between the two groups was reduced to 0.34 (95% CI 21.65 to
2.33, p=0.74) in favour of Group B.
The groups were broadly balanced at baseline in both clinical
and demographic characteristics (Table 1). However, as a result of
the slight imbalance between the groups in age, previous treatment
history, and use of biological washing powder, a generalised linear
model was used to adjust for these baseline differences. This
analysis gave similar results to the univariate t-test analysis. The
difference between the two groups was 0.54 (95% CI 21.54 to
2.62, p=0.61) in favour of Group B. Additional sensitivity analyses
excluding cases where the nurse became unblinded (n=24), where
a different nurse was required to perform the follow-up SASSAD
assessment due to maternity leave (n=14), and excluding outliers
(change scores outside the range of 63 SD) (n=3), supported the
primary ITT analysis.
The additional per-protocol analysis excluding protocol viola-
tors also supported the primary ITT analysis (Table 2).
Overall, there were no statistically significant differences
between the groups for any of the objective secondary outcomes.
These were the grouped eczema severity scores, the time spent
moving during the night, and use of topical medication (Tables 2
and 3). Small but statistically significant differences in favour of the
intervention were observed in three of the four unblinded
secondary outcomes that were recorded by the participants or
their carers (Patient Oriented Eczema Measure; number of well-
and totally controlled weeks; and DFI score) (Table 4).
Saliva samples were screened for the two most common
mutations in the filaggrin gene, R501X and 2282del4. Of the
314 participants with test results, 94 (30%) had at least one
mutation in the filaggrin gene.
The planned subgroup analysis including children with complete
SASSAD data and at least one mutation of the filaggrin gene
(n=92) supported the primary analysis and showed no additional
benefit for participants with filaggrin gene mutations (Table 2).
Adverse events were not formally collected as the trial involved
the use of a commonly available domestic water softening unit,
with provision for mains drinking water while the water softening
unit was installed. Nevertheless, the parents of two participants
believed their child’s eczema had worsened as a direct result of
installation of the water softener and asked to have the unit
removed. Parents of a third participant expressed concern that the
water softener appeared to be making their child’s eczema worse,
but continued to take part in the trial.
Results of the cost-effectiveness analyses are available in the full
trial write-up [14]. It was not appropriate to conduct analyses
lookingat possibleduration of benefitand speed ofonset ofbenefitin
the final observational part of the study as there was no primary
treatmenteffect.Nevertheless,theSASSADscorescollectedbetween
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Characteristics Group A: Water Softener+Usual Care Group B: Usual Care
N enrolled 170 166
N in ITT population 159 164
Age
Mean age (SD) 5.8 (4.2) 5.1 (4.0)
Sex, N (%)
Male 89 (56) 96 (59)
Female 70 (44) 68 (41)
Ethnicity, N (%)
White 124 (78) 125 (76)
Non-white 34 (21) 38 (23)
Not stated/unknown 1 (1) 1 (1)
Previous treatment history, N (%)
a
High-strength corticosteroids/calcineurin inhibitors 91 (57) 80 (49)
Low-strength corticosteroids/calcineurin inhibitors 57 (36) 73 (45)
None 11 (7) 11 (7)
Filaggrin status, N (%)
Presence of mutation 45 (28) 47 (29)
Absence of mutation 103 (65) 109 (66)
Unknown 11 (7) 8(5)
Food allergy, N (%)
b
No 97(63) 102 (64)
Yes 58 (37) 58 (36)
Baseline SASSAD, N (%)
c
Mean (SD) 24.6 (12.7) 25.9 (13.8)
Median (IQR) 21 (15–32) 22.5 (15.5–33.5)
10–19 72 (45) 68 (41)
.20 87 (55) 96 (59)
Water hardness (mg/l calcium carbonate)
Mean (SD) 309 (50) 310 (58)
Median (IQR) 308 (274–342) 300 (270–340)
Washing powder, N (%)
d
Biological 20 (13) 12(7)
Fabric softener, N (%)
e
Yes 69 (44) 81 (49)
Bathing freq at home, times per week
f
Median (IQR) 5 (3–7) 4 (3–7)
Bathing frequency away from home, times per week
g
Median (IQR) 0 (0–1) 0 (0–0)
Swimming frequency, N (%)
h
Never 56 (35) 66 (40)
Less than once a month 53 (34) 52 (32)
More than once a month 49 (31) 46 (28)
aHigh-strength medication consists of those using potent or very potent steroids, or mild or moderate calcineurin inhibitors. Low-strength medication consists of those
using mild or moderate steroids only.
bThere were eight missing values for the food allergy variable.
cThere was one missing value for SASSAD at baseline as the patient was randomised on the strength of a partial SASSAD score that excluded the child’s legs.
dThere were four missing values for the washing powder variable.
eThere were three missing values for the fabric softener variable.
fThere was one missing value for the bathing at home frequency variable.
gThere were 12 missing values for the bathing away from home variable.
hThere was one missing value for the swimming frequency variable.
IQR, interquartile range.
doi:10.1371/journal.pmed.1000395.t001
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turned off for Group A and installed for Group B; Figure 2).
Discussion
Main Findings
This study found no benefit of using an ion-exchange water
softener in addition to usual care in children with eczema. There
were no clinically important differences between the treatment
groups for any of the blinded outcomes. Furthermore, the 95%
CIs around the primary efficacy estimates were narrow. An
improvement of 1.37 points in favour of water softeners (the lower
95% CI), to 2.69 points in favour of usual care (the upper 95% CI)
makes it unlikely that a clinically useful benefit has been excluded
by chance. In order to understand the clinical relevance of these
results it is helpful to consider the proportion of participants who
Table 2. Objective outcome measures (primary and secondary).
Measures
Group A: Water
Softener+Usual Care Group B: Usual Care
Difference and 95%
CI (A–B) p-Value
Change in SASSAD score from baseline to week 12: Primary ITT analysis
N
a 159 164
Week 0, mean (SD) 24.6 (12.7) 25.9 (13.8)
Week 12, mean (SD) 19.6 (12.8) 20.2 (13.8)
Change, mean (SD) 25.0 (8.8) 25.7 (9.8) 0.66 (21.37 to 2.69) 0.53
Change in SASSAD score from baseline to week 12: Per protocol analysis
N
b 99 115
Week 0, mean (SD) 25.3 (13.7) 26.3 (14.5)
Week 12, mean (SD) 20.8 (13.6) 20.0 (13.4)
Change, mean (SD) 24.5 (9.3) 26.3 (9.9) 1.87 (20.73 to 4.47) 0.16
Change in SASSAD score from baseline to week 12 in participants who had at least one mutation on the filaggrin gene
N
c 45 47
Week 0, mean (SD) 27.2 (13.4) 26.7 (13.4)
Week 12, mean (SD) 22.0 (13.4) 20.4 (13.9)
Change, mean (SD) 25.2 (9.5) 26.3 (6.8) 1.05 (22.36 to 4.47) 0.54
Change in the percentage of the night spent moving
N
d 114 121
Week 0, mean (SD) 21.2 (7.7) 22.4 (9.7)
Week 12, mean (SD) 24.7 (15.9) 26.5 (17.9)
Change, mean (SD) 3.5 (14.5) 4.1 (16.8) 20.64 (24.68 to 3.40) 0.76
Total amount (in grams) of all medication used between baseline and week12
N
e 160 153
Total medication used, mean (SD) 58.4 (96.8) 67.3 (97.3) 28.90 (230.50 to 12.70) 0.42
aBased on participants with evaluable data at baseline and week 12.
bExcluding participants deemed to be protocol violators by the Protocol Violators Group.
cBased on participants who had at least one mutation and data at baseline and week 12.
dBased on participants with at least 3 nights of evaluable data at baseline and week12.
eBased on participants with available data at week 12.
doi:10.1371/journal.pmed.1000395.t002
Table 3. Categories of improvement in eczema severity (SASSAD) scores.
Level of Improvement
Group A: Water
Softener+Usual Care Group B: Usual Care Total p-Value
N randomised 170 166 336
N
a 159 164 323
Same or worse (#0%) 39 (25%) 42 (26%) 81 (25%)
Small (.0% and #20%) 37 (23%) 30 (18%) 67 (21%)
Good (.20% and #50%) 53 (33%) 56 (34%) 109 (34%)
Excellent (.50%) 30 (19%) 36 (22%) 66 (20%) 0.62
aNumber of participants with evaluable data at both week 0 and week 12.
doi:10.1371/journal.pmed.1000395.t003
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trial (52% in the water softeners group and 56% in the usual care
group).
Performing a per-protocol analysis based on those with
maximum exposure to the water softener, and excluding those
who had changed their usual eczema treatments during the trial,
did not change the overall interpretation of these results.
It is possible that water softeners could prove beneficial in the
absence of a change in disease severity if the softeners resulted in a
steroid-sparing effect. However, measurement of the amount of
topical steroid or calcineurin inhibitors applied during the trial
showed that both groups used roughly equivalent amounts of
topical therapy throughout the 12-week study period.
Of the four unblinded secondary outcomes, all except EQ-5D
showed small but statistically significant differences in favour of the
water softener group. However, the magnitude of improvement
seen in these outcomes was small and unlikely to be clinically
significant. It is most likely that these differences were a result of
response bias.
Of the children involved in the study, just under 30% had at
least one filaggrin mutation, but these children showed no
additional benefit compared to children without the mutation.
Limitations
This was an adequately powered randomised trial, with high
follow-up rates, that placed special emphasis on objective outcome
measures to minimise response bias. Previous pilot work demon-
strated the need for an objective outcome, as blinding participants
withashamunitwasonlypartlysuccessful(duetothedifferentfeelof
softened water and the amount of suds generated) [14]. It is possible
thatour emphasisonobjective outcomes meantthat some important
potential benefits were not captured in the primary analysis. Other
factors, such as improvements in quality of life, or a reduction in
symptoms (such as perception of skin dryness), may be important
drivers in determining whether or not parents choose to buy a water
softener. Indeed, many parents in the trial reported small health
benefits,andjustover50%chosetobuythewatersoftenerattheend
of the trial. The reasons participants gave for purchasing the units
included perceived improvements in the eczema (66%); wider
benefits of the softeners (27%); or both reasons (7%).
It is also possible that treatment effects were masked by the
usual eczema care, but given the generally low use of topical
corticosteroids and calcineurin inhibitors in both groups, this is
unlikely to be the case.
This trial was of relatively short duration, and it is possible that
the trial was insufficient to capture any treatment effect. However,
both treatment groups improved in disease severity during the
trial, and there was no hint that the intervention group was
starting to show more improvement than the control group
towards the end of the 12-week period. Anecdotal reports from
patients returning from holidays claim benefits within 1–2 weeks.
This led us to anticipate that if a treatment response existed, it was
likely to occur more quickly than 12 weeks.
The continued use of soap and soap products during the trial
may have limited the observed benefits if families were using too
Table 4. Un-blinded secondary outcome measures.
Measures
Group A: Water
Softener+Usual Care Group B: Usual Care Difference and 95% CI (A–B) p-Value
Change in Patient Oriented Eczema score from baseline to week 12
N
a 161 162
Week 0, mean (SD) 16.8 (6.0) 16.6 (5.6)
Week 12, mean (SD) 11.1 (7.1) 13.0 (6.7
Change, mean (SD) 25.7 (7.2) 23.6 (6.7) 22.03 (23.55 to 20.51) 0.009




WCW, mean (SD) 8.3 (3.8) 7.3 (4.1) 0.99 (0.04 to 1.95) 0.04




TCW, mean (SD) 2.9 (3.5) 1.7 (2.8) 1.19 (0.43 to 1.95) 0.002
Change in DFI score from baseline to week 12
N
a 151 158
Week 0, mean (SD) 10.0 (6.8) 11.2 (7.3)
Week 12, mean (SD) 6.8 (6.0) 9.3 (7.1)
Change, mean (SD) 23.2 (6.2) 21.8 (5.4) 21.33 (22.63 to 20.03) 0.05
Change in EQ-5D score from baseline to week 12
N
a 112 112
Week 0, mean (SD) 0.690 (0.298) 0.693 (0.274)
Week 12
d, mean (SD) 0.810 (0.236) 0.759 (0.245)
Change, mean (SD) 0.119 (0.269) 0.066 (0.250) 0.054 (20.015 to 0.122) 0.124
aNumber of participants with data at both baseline and week12.
bWCW=2 days or less with an eczema bother score .4 and 2 days or less where stepping up of treatment was needed.
cTCW=0 days with an eczema bother score .4 and 0 days where stepping up of treatment was needed.
dIncrease in score represents an improvement in health-related quality of life.
doi:10.1371/journal.pmed.1000395.t004
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pragmatic study aimed to capture the effects of water softeners
according to standard advice. Evidence of how much soap was
actually used was not collected, as we did not want to change
participant’s behaviour by intensive monitoring.
Generalisability
We believe that this trial has good external validity, because
participants were recruited from eight UK centres and included
families of diverse socioeconomic backgrounds. Every effort was
made to include participants who lived in rented accommodation
as well as home owners. The results are applicable only to children
with moderate to severe eczema, and it is possible that water
softening is beneficial for milder forms of eczema, or in adults with
other eczema types.
One possible reason for the discrepancy between our null trial
findings and those of previous observational studies may be that
water hardness has an effect on the primary prevention of
eczema, rather than on the treatment of established eczema. The
current study did not address the issue of prevention of new cases
of eczema, which could be investigated by means of a further
RCT including families at risk of eczema. An alternative
explanation could be that the children in the observational
studies ingested the water. In other words, it is possible that
ingestion of hard water or a component to water that is related to
water hardness actually induces skin inflammation directly or
indirectly through inflammatory gene interactions, although we
are not aware of any such potential mechanisms from the
literature to date.
Interpretation
The results of this study are clear, and as a result we cannot
recommend the use of ion-exchange water softeners for the
treatment of moderate to severe eczema in children. Whether or
not the wider benefits of installing a water softener in the home are
sufficient to justify the purchase of a softener is something for
individual householders to consider on a case-by-case basis.
Supporting Information
Text S1 Protocol and analysis plan.
Found at: doi:10.1371/journal.pmed.1000395.s001 (0.42 MB
PDF)
Text S2 CONSORT checklist.
Found at: doi:10.1371/journal.pmed.1000395.s002 (0.22 MB
DOC)
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Background. Eczema (sometimes referred to as atopic
dermatitis) is a chronic, inflammatory skin condition that
affects about 20% of school children in developed countries.
Eczema is often associated with other conditions, such as
asthma, hay-fever and food allergy and can cause intractable
itching leading to thickened skin, bleeding, secondary
infection, sleep loss, poor concentration, and psychological
distress. Current topical treatments for eczema have side
effects, for example, topical corticosteroids may cause skin
thinning and the long term safety of topical tacrolimus and
pimecrolimus has yet to be determined. Therefore, there is a
lot of interest in exploring the benefits of non-
pharmacological treatments that have no apparent side
effects.
Water hardness ($200 mg/l calcium carbonate) has become
a recent focus of attention.
Why Was This Study Done? In addition to some
epidemiological evidence linking increased water hardness
with increased eczema prevalence, there have been
widespread anecdotal reports of improvement in the skin
of children with eczema when the family has moved from a
hard to a soft water area. In addition, some patients report
how their eczema symptoms have rapidly improved
following the installation of a water softener. However, to
date there have been no relevant published trials evaluating
the potential benefit of water softeners for eczema. Given
the lack of evidence, the high public interest in their
potential benefit and the low risk of adverse effects, the
researcher conducted a study to assess whether the
installation of an ion-exchange water softener reduces the
severity of eczema in children with moderate to severe
eczema.
What Did the Researchers Do and Find? The researchers
did a pilot study that showed that it was not possible to
blind participants to their treatment allocation using real and
‘‘dummy’’ water softener units because the softened water
produced more soap suds. So the researchers conducted an
observer-blind randomised controlled trial in which they
used trained research nurses to conduct an objective
assessment of every participant’s skin. The researchers
recruited 336 children who all lived in hard water areas in
England. Eligible children were aged 6 months to 16 years
who had a diagnosis of eczema (in line with the UK working
party’s diagnostic criteria) and an eczema severity score of 10
or over. Participants were randomised to either installation of
an ion-exchange water softener plus usual eczema care, or
usual eczema care alone. Trained research nurses examined
each child’s skin at baseline and at 6, 12, and 16 weeks to
record changes in eczema severity. The researchers also
analysed any changes in symptoms over the study period
such as, sleep loss and itchiness, the amount of topical
corticosteroid/calcineurin inhibitors used, the Dermatitis
Family Impact questionnaire and the health related Quality
of Life (children’s version).
Although both treatment groups improved in disease
severity during the course of the trial, the researchers found
no difference between the treatment groups in the main
outcome—eczema severity. Similar finding were found for
night movement (scratching) and the use of topical
medications (creams/ointments applied to the skin), both
of which were blinded to intervention status. Nevertheless,
parents in the trial did report small health benefits, and just
over 50% chose to buy the water softener at the end of the
trial because of perceived improvements in the eczema and
the wider benefits of water softeners. It is unclear how much
of this effect can be explained by prior belief in the
effectiveness of the water softeners for the treatment of
eczema.
What Do These Findings Mean? The results of this study
suggest that water softeners provide no additional clinical
benefit to usual care in children with eczema so the use of
ion-exchange water softeners for the treatment of moderate
to severe eczema in children should not be recommended.
However, it is up to each family to decide whether or not the
wider benefits of installing a water softener in their home are
sufficient to consider buying one.
Additional Information. Please access these Web sites via
the online version of this summary at http://dx.doi.org/10.
1371/journal.pmed.1000395.
N The UK’s NHS presents information on eczema for patients
and families
N MedlinePlus gives information for patients, families, and
caregivers on eczema and other similar conditions
N The National Eczema Society in the UK provides informa-
tion and a helpline for eczema patients, families, and
caregivers
N Medinfo provides information for eczema patients
N Wikipedia has more information about water softening
(note that Wikipedia is a free online encyclopedia that
anyone can edit; available in several languages)
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